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In 2016, the World Health Organization (WHO) set a target for eliminating viral hepatitis as a 36 
major public health threat by 2030. However, while today’s highly effective and well-37 
tolerated pangenotypic direct-acting antiviral (DAA) regimens have maximized simplification 38 
of HCV treatment, there remain a plethora of barriers to HCV screening, diagnosis and 39 
linkage to care. As of 2017, only 19% of the estimated 71 million individuals living with 40 
chronic hepatitis C virus (HCV) worldwide were diagnosed and in 2015–2016, only 21% of 41 
diagnosed individuals had accessed treatment. Simplification and decentralization of the 42 
HCV care cascade would bolster patient engagement and support the considerable scale-up 43 
needed to achieve WHO targets. Recent developments in HCV screening and diagnosis, 44 
together with reduced pre-treatment assessment and on-treatment monitoring 45 
requirements, can further streamline the care continuum, ensuring patients are linked to 46 
care quickly and earlier in the disease course, and minimize clinic visits. 47 
48 
Main Concepts and Learning Points 49 
Today’s highly effective, well-tolerated, all-oral, direct-acting antiviral combinations for the treatment 
of chronic hepatitis C virus infection have made elimination of the virus theoretically achievable by 
the World Health Organization’s target of 2030 
Despite the availability of curative hepatitis C virus treatments, most persons infected with hepatitis C 
virus remain untreated 
Recent developments in hepatitis C virus screening and diagnostic procedures, as well as reduced pre-
treatment assessments and on-treatment monitoring requirements, can simplify the hepatitis c virus 
continuum of care 
Simplification of the hepatitis c virus care cascade would facilitate patient engagement and support 
the current concerted effort towards hepatitis c virus elimination 
The journey from hepatitis c virus screening to cure can be achieved in as few as five steps and in as 
little as 20 to 24 weeks 
50 
51 
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Introduction 52 
The availability of highly effective, well-tolerated, all-oral, direct-acting antiviral 53 
(DAA) combinations for the treatment of chronic hepatitis C virus (HCV) infection has made 54 
the elimination of HCV a theoretically achievable goal within the next decade.[1] In May 55 
2016, the World Health Organization (WHO) adopted their “Global Health Sector Strategy 56 
on Viral Hepatitis, 2016‒2021,” which aims to eliminate viral hepatitis as a major public 57 
health threat by 2030 by reducing new chronic infections by 90% and mortality by 65%. To 58 
achieve this goal, 90% of individuals with chronic HCV infection need to be diagnosed, and 59 
80% of those need to be treated.[2] Worldwide, however, the majority of people infected 60 
with HCV are not diagnosed and, therefore, remain untreated. In 2017, an estimated 71 61 
million individuals were living with chronic HCV worldwide.[3] Of these, it is thought that 62 
only 13.1 million (19%) knew of their infection and only 5 million of those (38%) had 63 
accessed treatment by the end of 2017.[3] Simplification of the HCV care cascade, ideally at 64 
all steps in the continuum of care, would help to ensure that more patients remain engaged 65 
in the care pathway and ultimately support the considerable scale-up needed to achieve 66 
WHO targets.[4] In this article, we review the existing care pathway and discuss potential 67 
opportunities in which the patient journey from HCV screening to cure could be 68 
streamlined. 69 
 70 
Overview of the current HCV care pathway 71 
Depending on the setting, and despite a current concerted effort towards 72 
simplification, the current HCV care pathway can be visualized as a sequence of anywhere 73 
up to 10 steps (Fig. 1A), from screening to cure, as advocated by international guidelines for 74 
HCV management, such as those from the American Association for the Study of Liver 75 
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Diseases (AASLD)/Infectious Diseases Society of America (IDSA),[5] the European Association 76 
for the Study of the Liver (EASL),[6] and WHO.[7] The steps can be grouped into three 77 
distinct phases: screening and diagnosis, pre-treatment, and treatment and monitoring 78 
(including post-treatment follow-up). 79 
 80 
Screening and Diagnosis 81 
The screening and diagnosis phase includes screening for the presence of anti-HCV 82 
antibodies and confirming active HCV replication. Traditionally, screening of individuals at 83 
risk of HCV infection using an anti-HCV antibody test has been widely recommended, with 84 
periodic retesting for those at ongoing risk of (re)infection, such as people who inject drugs 85 
(PWID).[5-7] However, recent guideline updates have seen the broadening of this 86 
recommendation to one-time, routine, opt-out HCV testing for all individuals aged 18 years 87 
and older, with some also recommending testing in the prenatal setting during each 88 
pregnancy.[3,5,8,9] Other screening strategies include birth cohort testing or screening the 89 
general population in areas where HCV seroprevalence is intermediate (≥2%) or high 90 
(≥5%).[6,7] In individuals who are anti-HCV antibody positive, HCV replication is confirmed 91 
using a qualitative/quantitative HCV RNA test.[5-7] HCV core antigen detection and 92 
quantification may also be used to diagnose acute or chronic HCV infection.[6,7] With both 93 
assays, only the presence, not the amount, of marker is used for medical decisions. For 94 
payer reimbursement in some regions, namely the United States and Canada, two separate 95 
HCV RNA tests at least 6 months apart are required to confirm a diagnosis of chronic HCV 96 
infection. Guidelines now recommend that individuals with acute HCV infection are linked to 97 
appropriate care with a healthcare provider who will administer comprehensive 98 
management, rather than waiting for progression to chronic disease.[5,10]  99 
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 100 
Pre-Treatment Phase 101 
For many patients, the pre-treatment phase includes an initial visit to a specialist 102 
(hepatologist, gastroenterologist, or infectious disease specialist) for pre-treatment 103 
assessments and selection of an appropriate HCV treatment. Prior to treatment initiation, a 104 
series of recommended tests are performed to identify viral and host factors that may 105 
impact the choice of treatment, prognosis, and/or required follow-up. In the DAA era, and 106 
with pangenotypic options available, the number of pre-treatment tests has been reduced; 107 
in particular, viral factors (eg, HCV genotype/subtype, presence of HCV drug resistance–108 
associated substitutions) that may have previously impacted viral response and, therefore, 109 
treatment choice are not always required. However, it is still generally important to assess 110 
other active infections, such as hepatitis B virus (HBV) or human immunodeficiency virus 111 
(HIV), and confirm HCV genotype where appropriate.[5-7] Furthermore, it is considered 112 
good clinical practice to assess the degree of liver fibrosis in order to inform treatment 113 
decisions.[5-7] 114 
 115 
Treatment and Monitoring Phase 116 
In most cases, the choice of DAA and treatment duration have been based on HCV 117 
genotype, liver disease severity, and prior HCV treatment status. AASLD/IDSA guidance and 118 
2018 EASL recommendations advocate ribavirin-free DAA regimens, preferably 119 
pangenotypic if available (ie, those effective against the main HCV genotypes 1‒6), for HCV 120 
treatment-naïve or -experienced adults without cirrhosis or with compensated cirrhosis.[3] 121 
Ribavirin is required in patients with decompensated cirrhosis.[5,6] In addition, EASL 122 
guidelines recommend combination regimens comprising two rather than three DAAs to 123 
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minimize the risk of adverse effects or drug–drug interactions.[6] Finally, WHO guidelines 124 
only recommend pangenotypic DAA regimens for all adults with or without cirrhosis.[7] 125 
Although DAAs are generally well-tolerated, patients should be assessed for adverse 126 
events or potential drug–drug interactions at each visit or, according to WHO guidelines, at 127 
the end of treatment.[5-7] HBV reactivation during or after DAA treatment has been 128 
reported in patients who are hepatitis B surface antigen–positive and not receiving HBV 129 
antiviral therapy.[5] Therefore, patients meeting criteria for active HBV infection should be 130 
started on HBV antiviral therapy. Patients with low or undetectable HBV DNA levels can 131 
either receive prophylactic HBV therapy or be monitored for HBV reactivation during and 132 
immediately after HCV DAA therapy; HBV therapy should be initiated in patients with 133 
evidence of HBV reactivation.[5-7] 134 
The final monitoring step is assessment of HCV cure, defined as a sustained virologic 135 
response (SVR; ie, undetectable HCV RNA) 12 weeks after completion of treatment 136 
(SVR12).[5-7] Some guidelines suggest SVR at 24 weeks after completion of treatment 137 
(SVR24) can also be used to define cure[6,7]; however, because of the high rate of 138 
concordance between SVR12 and SVR24 (sensitivity and specificity of 99% and 98%, 139 
respectively), the US Food and Drug Administration, and AASLD/IDSA guidelines, have 140 
defined HCV cure as SVR12.[5,11] Some patients may require additional monitoring, for 141 
instance to minimize drug–drug interactions between HCV DAAs and anti-HIV medications 142 
or immunosuppressants that could jeopardize graft success in liver transplant 143 
recipients.[5,6] Patients with advanced cirrhosis should also be monitored closely during 144 
treatment, and for hepatocellular carcinoma (HCC) after treatment.[5-7] 145 
 146 
Simplifying the HCV Care Pathway 147 
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The current HCV care pathway is complex and often difficult to navigate for many 148 
patients, with multiple office visits, blood draws, assessments, and interactions with 149 
different healthcare providers and payers. This level of continuous care can be a particularly 150 
challenging barrier in some populations that require specific public health approaches 151 
because of a high incidence of HCV, high prevalence of HCV, stigma, discrimination, 152 
criminalization or vulnerability, and/or difficulty accessing healthcare services, such that 153 
they would benefit from a streamlined care pathway.[7] Examples of such populations 154 
include PWID, prisoners, homeless individuals, migrants, those in rural communities with 155 
poor access to care, those struggling with mental health or substance use disorders, some 156 
groups of men who have sex with men, sex workers, and indigenous populations who are 157 
historically less engaged in healthcare. In addition, the current pathway requires high-level 158 
laboratory and clinical capabilities to diagnose infection, identify the HCV genotype, assess 159 
fibrosis, and monitor treatment. These requirements potentially create barriers for HCV care 160 
management. 161 
Based on recent advances in diagnostic techniques and HCV treatments, the current 162 
HCV care pathway can be streamlined (Fig. 1B), and simplification of care is an increasing 163 
focus within the field of HCV treatment.[4] Simplification will potentially have multiple 164 
benefits, including better allocation of resources to diagnose and treat more patients 165 
(expanding access and coverage), acceleration of treatment initiation (linkage to care), 166 
reduction in HCV transmission among high-risk populations (treatment as prevention), 167 
improvement in patient adherence, facilitation of task-sharing/patient management by non-168 
specialists, and lowering the long-term medical costs of untreated HCV infection, such as 169 
those associated with advanced liver disease, extra-hepatic complications of HCV infection, 170 
or liver transplant. 171 
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For many patients, the ideal HCV care pathway would involve diagnosis, pre-172 
treatment work up, and treatment initiation in a single day. A US study modeled the impact 173 
of a hypothetical “consolidated” HCV care pathway that required at least two visits for 174 
patients to receive treatment.[12] In this scenario, a positive anti-HCV test led immediately 175 
to an HCV RNA test, HCV genotyping, and fibrosis staging, which took place during a single 176 
visit. Referral to a specialist was required only for patients with moderate to advanced 177 
fibrosis (METAVIR stage ≥F2); therefore, an estimated 40% of patients could be managed by 178 
their primary care provider. Compared with the current HCV care pathway that requires at 179 
least four visits before receiving treatment, the consolidated pathway reduced the 180 
percentage of patients lost to follow-up from screening to treatment from 71‒76% 181 
(depending upon the insurance provider) to 4‒5%. Therefore, reducing the steps in the care 182 
pathway increased the number of patients who learned of their HCV status, were linked to 183 
care, and received HCV treatment. The cost to identify and link to care one additional 184 
patient with HCV was $1586‒$2546 with the current HCV care pathway and $212‒$548 with 185 
the consolidated pathway.[12] However, these findings may not be generalizable to all 186 
geographical settings or certain high-risk populations. 187 
 188 
Simplifying the Screening and Diagnosis Phase 189 
Screening and diagnostic services need to reach much larger numbers of individuals 190 
with HCV infection to achieve the WHO elimination target of 90% diagnosed by 2030. 191 
Strategies to increase anti-HCV screening and diagnosis rates include risk factor–based 192 
screening, universal screening in specific populations, simplification of sampling using 193 
capillary whole blood, dried blood spot (DBS) testing, and point-of-care (PoC) testing using 194 
rapid diagnostic tests (RDTs). 195 
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 196 
Screening Programs 197 
Risk factor–based anti-HCV screening has previously been a prominent feature of 198 
international guidelines. However, screening for specific risk factors for HCV infection (ie, 199 
risk behaviors or exposures) has largely been unsuccessful because of patients’ reluctance 200 
to disclose these risks and provider limitations in collecting risk information.[5] Population-201 
based screening methods may be more successful (ie, identifying and screening populations 202 
that have a relatively high prevalence of HCV infection). For example, in the United States, 203 
50% of all HCV infections occur in individuals born between 1945 and 1965; therefore, one-204 
time HCV testing has been recommended in this birth cohort.[13] Nevertheless, screening 205 
rates are still low in this population because of, among other reasons, the stigma associated 206 
with HCV infection, the asymptomatic course of the disease, the lack of awareness of testing 207 
recommendations, and low healthcare engagement of the most at-risk populations.[14]  208 
However, recent guideline updates have seen recommendations for screening 209 
broaden to include routine one-time HCV testing for all individuals aged 18 years and 210 
older.[3,5,8,9] Practical implementation measures, such as electronic medical record 211 
prompts, that have been shown to significantly increase screening rates in individuals born 212 
between 1945 and 1965 may help to facilitate universal screening and alleviate any stigma 213 
related to the disease. For example, in one study of this demographic group, screening rates 214 
increased from 7.6% during the 6 months before their introduction to 72% over the year 215 
after their introduction.[15] 216 
PWID have been identified as a priority population for HCV elimination. Worldwide, 217 
approximately 40% of people with recent injecting drug use are infected with HCV and 9% of 218 
all people living with HCV infection are those who recently injected drugs, with wide 219 
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variation among countries.[16] It has been estimated that 43% of all new HCV infections 220 
could be prevented over 12 years (2018–2030) if the HCV transmission risk associated with 221 
PWID was removed over that period.[17] Uptake of HCV treatment in this group is 222 
historically low,[18] despite guideline recommendations to regularly screen PWID for 223 
HCV.[5-7] The challenge for screening this population is the lack of engagement with 224 
traditional sources of healthcare; therefore, alternative options must be explored. One 225 
successful strategy is to integrate HCV screening programs into harm reduction and 226 
community outreach facilities, thereby offering a comprehensive “one-stop strategy” at the 227 
PoC for HCV screening and diagnosis, treatment initiation, and follow-up. Such approaches 228 
have been successfully implemented in several countries including France,[19] 229 
Switzerland,[20] and the United States.[21] In Scotland, the launch of the Hepatitis C Action 230 
Plan introduced DBS sampling into community drug services to increase access to 231 
testing.[22] Between the pre–Action Plan (1999–2006) and Action Plan (2007–2011) 232 
periods, the average number of annual tests increased from 67 to 973; the percentage of 233 
individuals testing positive for HCV also increased across these periods (from 19% to 38%). 234 
Unfortunately, screening birth cohorts and high-risk populations such as PWID will 235 
not find all of the remaining individuals infected with HCV. Achieving WHO elimination 236 
targets will require the adoption of broader, simpler screening policies. Different regional 237 
strategies will be needed because of the variable global epidemiology of HCV infection.[16] 238 
One strategy under consideration is universal anti-HCV screening of all adults. Egypt, which 239 
has the highest prevalence of HCV worldwide and access to low-cost generic DAA 240 
treatments, has embarked on one such program: following a campaign of targeted 241 
screening, all adults aged 18 years and older are now being screened.[23] This approach 242 
may be too costly in regions with low HCV prevalence because of the large number of 243 
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patients needed to be screened. However, modeling studies in France and the United States 244 
have shown universal screening can be cost-effective in low prevalence regions.[24,25] 245 
Indeed, the US Preventative Services Task Force has recently updated their 246 
recommendations to include HCV screening for all adults 18–79 years of age.[8] Likewise, 247 
the US Centers for Disease Control & Prevention (CDC) recently updated their 248 
recommendations to include screening of all adults aged 18 years and older in addition to all 249 
pregnant women; except in settings where the prevalence of HCV is less than 0.1%.[9] 250 
HCV screening in pregnancy represents an important opportunity for healthcare 251 
provider interaction with women of childbearing age, in whom rates of HCV have been 252 
increasing in recent years.[26] The prevalence of HCV antibodies in pregnant women is 253 
thought to be 0.1–3.6% worldwide, and some studies suggest that chronic HCV infection is 254 
associated with an increased risk for adverse neonatal outcomes.[27] Furthermore, vertical 255 
transmission of HCV from mother to child will occur in up to 5% of cases of HCV 256 
monoinfection and is a common source of HCV infection in children.[28]   257 
Around 3.5 million children are estimated to be infected globally,[28] representing 258 
an important pool of unidentified HCV cases, with as many as 95% of HCV-infected children 259 
in the United States of America remaining undiagnosed.[29] In one study including 119 260 
perinatally infected patients, 38% of those aged >33 years had developed cirrhosis, despite 261 
the low prevalence of traditional risk factors.[30] 262 
Alternatively, pragmatic approaches to screening strategies, such as random 263 
selection or using a hub-and-spoke model as trialed in Italy, can provide a practical 264 
compromise between universal and targeted screening.[31] 265 
Regardless of the model employed and populations targeted, screening to identify 266 
undiagnosed cases is vital in achieving elimination targets. 267 
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 268 
Virologic Tools to Simplify HCV Screening 269 
PoC testing provided outside traditional centralized laboratories can be used with 270 
the goal of delivering test results to patients during the same visit.[32] PoC testing relies 271 
extensively on the use of one of the many RDTs available for anti-HCV antibody detection, 272 
several of which are prequalified by WHO.[33] RDTs can be performed in 20 minutes for 273 
anti-HCV antibodies using whole blood obtained by venipuncture or finger prick, or oral 274 
fluid. Anti-HCV antibody RDTs have excellent sensitivity and specificity compared with ELISA-275 
based laboratory methods (98% and 100%, respectively).[34] RDTs are valuable in high-276 
throughput settings where results are needed quickly, such as prisons and harm reduction 277 
programs. An example of the value of RDTs within a harm reduction setting is provided by 278 
Bregenzer et al., where the introduction of an anti-HCV antibody RDT led to 23.9% of PWID 279 
undergoing HCV screening, compared with only 2% prior to its introduction.[35] 280 
Confirmation of infection after detection of anti-HCV antibodies requires HCV RNA or core 281 
antigen testing. A few PoC HCV RNA assays, which generate results from plasma or whole 282 
blood within 60 to 90 minutes, are available.[32] The increasing availability of such assays in 283 
high-income settings has the potential to transform HCV testing. In low-income countries, 284 
providers need to take advantage of the availability of such technologies, which to date 285 
have typically been used for HIV or tuberculosis testing. 286 
To meet the WHO goal of identifying 90% of all HCV-infected individuals, PoC testing 287 
needs to be implemented into non-traditional settings to capture individuals not actively 288 
engaged in healthcare, including emergency departments, obstetric centers, surgical and 289 
psychiatric wards, dental clinics, and pharmacies.[36-41] Potential benefits of increased PoC 290 
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testing include reducing the number of clinic visits, which may increase screening and 291 
treatment rates, and reducing late presentation, which is common in patients with HCV.[42]  292 
Using DBS samples is an alternative method to PoC testing. A few drops of fingerstick 293 
whole blood are placed onto a special absorbent filter paper. After desiccation, DBS can be 294 
shipped as non-hazardous materials using regular mail or courier services to reference 295 
laboratories for anti-HCV antibody and HCV RNA assessments.[32] DBS diagnostic accuracy 296 
is high for anti-HCV antibodies (sensitivity, 96.1%; specificity, 99.2%) and HCV RNA 297 
(sensitivity, 97.8%; specificity, 99.2%), with no relevant differences in diagnostic accuracy 298 
according to the type of test used.[43] DBS has distinct advantages over blood and oral fluid 299 
in terms of ease of transport and storage and may be particularly useful in low- and middle-300 
income countries with high HCV prevalence and limited healthcare infrastructure. In high-301 
income countries, DBS could be used where facilities and treatment for PWID or migrant 302 
populations are community located and staffed by workers with limited clinical training.  303 
 304 
Methods to Improve Linkage to Care 305 
In addition to increasing screening rates, loss to follow-up between screening and 306 
diagnosis must be reduced. Studies in Europe and the United States show that 69% and 47% 307 
of screened patients, respectively, did not receive a confirmatory diagnosis of HCV 308 
infection.[44,45] Some countries have higher diagnosis rates, particularly those with 309 
national screening plans, such as France (74%) and Australia (75%).[46,47] Reinforcing the 310 
link between screening and diagnosis will ensure better identification of infected individuals 311 
and improve rates of retention in the HCV care pathway. The screening and diagnosis phase 312 
will continue to be a two-step process until it becomes more cost-effective to perform a 313 
single HCV RNA test to confirm active HCV infection (eg, in areas with very high HCV 314 
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prevalence). Alternatively, advances such as reflex testing combine these steps into a single 315 
clinic visit.  316 
Reflex HCV RNA testing, in which a positive anti-HCV test triggers an immediate HCV 317 
RNA test on the same sample, eliminates an extra visit for a new sample and enables more 318 
rapid linkage to care.[12] Reflex HCV RNA testing, as used by the US Veterans Affairs (VA) 319 
system,[48] is important in large health systems, with centralized testing where most 320 
patients are actively engaged in care and undergoing phlebotomy rather than PoC 321 
testing.[48] However, this approach may be suitable for some field-based PoC approaches 322 
outlined above. AASLD/IDSA guidelines recommend that harm reduction programs offer 323 
anti-HCV testing with reflex or immediate confirmatory HCV RNA testing,[5] 2018 EASL 324 
recommendations state that reflex HCV RNA testing should be applied whenever 325 
possible,[6] and WHO guidelines include reflex HCV RNA testing as an approach to promote 326 
linkage to care in all patients with HCV.[7] 327 
Increases in screening and diagnosis rates will have a limited impact on WHO 328 
elimination targets without concomitant improvements in linkage to care. Although 329 
specialist referral may be required for some complex cases, most patients could be treated 330 
by their primary care provider if the providers were given adequate training.[7] Therefore, 331 
the role of the primary care provider is considered critical for expanding access to HCV care, 332 
especially in areas of high HCV prevalence.[49] Recently released “Simplified HCV Treatment 333 
Algorithms” from AASLD/IDSA reinforce the concept that less complex cases can be 334 
successfully managed by primary care providers with less intensive monitoring.[50,51] 335 
Indeed,  decentralizing HCV treatment to utilize primary care physicians significantly 336 
increased treatment uptake in PWID in Australia and New Zealand compared with hospital-337 
based specialist care (75% vs 34%), with significantly higher cure rates (49% vs 30%).[52] 338 
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Telementoring programs can be used to educate and support non-specialist providers. 339 
These programs take advantage of approaches such as videoconferencing and knowledge 340 
networks to establish close collaborations between HCV specialists and primary care 341 
providers or other healthcare professionals. One such program, the VA-Extension for 342 
Community Healthcare Outcomes (ECHO) program, demonstrated an increase in the rate of 343 
primary care provider–initiated HCV treatment from 2.5% to 21.4% (p<0.01) with program 344 
participation.[53] The ECHO model also demonstrated that HCV treatment administered by 345 
non-specialist providers was as safe and effective as that provided by specialists in 346 
underserved populations.[54] An alternative telementoring approach investigated in the 347 
ASCEND study indicates that under specialist oversight, nurse practitioners or primary care 348 
physicians only required a short 3-hour training session to treat patients as effectively as 349 
specialists.[55] Decentralizing HCV care from specialists to primary care providers, as well as 350 
other healthcare professionals such as addiction specialists, prison doctors, and advanced 351 
practice providers, would simplify the continuum of care and expand access to HCV 352 
treatments without compromising outcomes.[56] Furthermore, integrating HCV care 353 
pathways with those for common copathologies such as HIV, malaria or sexually transmitted 354 
diseases represents another important method for expanding access to HCV diagnosis and 355 
treatment[57-59] and can increase HCV diagnosis and treatment uptake.[59,60] 356 
 357 
Simplifying the Pre-Treatment Phase 358 
Assessing Liver Fibrosis 359 
Once chronic HCV infection has been confirmed, patients undergo several pre-360 
treatment assessments.[5-7] Staging of liver fibrosis by at least one method is required for 361 
all patients prior to treatment to determine the need for post-treatment monitoring (ie, bi-362 
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annual HCC ultrasound screening) in patients with advanced fibrosis (METAVIR score F3) or 363 
cirrhosis (METAVIR score F4).[5-7] If advanced fibrosis or cirrhosis is present, these patients 364 
should be referred to a specialist provider for their continued care requirements. However, 365 
the remaining population with HCV infection is evolving to generally be younger and have 366 
milder liver disease,[61,62] which may help to support more non-specialist provider 367 
involvement.  368 
Although biopsy was previously used for assessing liver fibrosis, the procedure is 369 
invasive and minor complications are common. Alternative, validated and non-invasive 370 
methods including serologic, physical, and imaging protocols have replaced biopsy and are 371 
preferred to stage liver fibrosis.[63] Simplifying the initial liver fibrosis assessment using 372 
non-invasive methods would enable decision-making by non-specialist providers, which 373 
would reduce referrals to specialists and improve access to care for patients. This could be 374 
particularly impactful for high-risk groups, such as PWID, who may already be managed in a 375 
number of health care settings.[64,65]  376 
The calculation of an aspartate aminotransferase (AST)-to-platelet ratio index (APRI) 377 
score using AST concentrations and platelet count has excellent negative predictive value 378 
and can identify patients not at risk for advanced liver fibrosis who could be easily managed 379 
by non-specialist providers.[63] In a prospective study in treatment-naïve patients 380 
chronically infected with HCV genotype 1‒6 and no history of cirrhosis, APRI ≤1 was used to 381 
select patients for 8 weeks’ treatment with the pangenotypic DAA combination 382 
glecaprevir/pibrentasvir.[66] The results showed that APRI ≤1 (mean, 0.41; range, 0.13‒383 
1.00) identified patients without cirrhosis who could then be appropriately treated by non-384 
specialist providers. Fibrosis-4 (FIB-4) is another tool that uses a formula based on age, AST, 385 
platelets, and alanine aminotransferase to score fibrosis.[63] FibroTest is a laboratory-386 
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ordered test using a proprietary formula based on age, gender, and five additional 387 
biomarkers.[63] Transient elastography (eg, FibroScan®) measures liver stiffness to assess 388 
fibrosis; in addition, other physical technologies have been developed to assess liver 389 
fibrosis.[63] FibroScan and FibroTest use may be restricted by cost and availability in 390 
resource-limited settings. AASLD/IDSA guidelines recommend liver biopsy and/or non-391 
invasive markers to evaluate liver fibrosis in patients with chronic HCV infection.[5] The new 392 
simplified algorithms from AASLD/IDSA emphasize the utility of non-invasive tests for 393 
fibrosis assessment.[50,51] EASL and WHO guidelines recommend non-invasive methods, 394 
especially APRI and FIB-4, outside specialty clinics in resource-limited settings.[6,7] 395 
 396 
HCV Genotype Determination 397 
With the introduction of pangenotypic DAAs, some guidelines consider that the need 398 
for HCV genotyping is reduced, particularly where tests are not available or not affordable, 399 
or to improve access by simplifying the care pathway.[5-7] However, identifying patients 400 
infected with genotype 3, particularly those who have cirrhosis, remains important because 401 
SVR rates can be impacted by prior HCV treatment experience or the presence of NS5A 402 
inhibitor resistance–associated substitutions at baseline.[5-7] Longer treatment durations, 403 
baseline resistance testing, or the addition of a third drug (eg, a DAA with another target or 404 
ribavirin) may be required in patients with HCV genotype 3 infection and cirrhosis. The 405 
decision to identify the HCV genotype may ultimately be one of cost-effectiveness (ie, 406 
relative cost of regimens without genotype 3 restrictions) and the epidemiologic profile of 407 
endemic HCV genotypes within specific regions. WHO guidelines stipulate that where HCV 408 
genotype 3 prevalence is <5%, genotyping could be excluded and a uniform pangenotypic 409 
treatment duration used.[7] 410 
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However, the prevalence of other potentially difficult-to-treat genotypes such as non-1a/b 411 
subtypes of GT1 or non-4a/d subtypes of GT4 are increasing worldwide, largely driven by 412 
migration from areas of high endemicity for these subtypes, such as sub-Saharan Africa 413 
(SSA).[67] These subtypes are associated with higher failure rates to earlier NS5A inhibitors 414 
than other subtypes, with sofosbuvir/velpatasvir/voxilaprevir the only currently approved 415 
re-treatment option for those failing initial NS5A-based regimens.[67] This potentially poses 416 
a barrier to re-treatment success, as there is limited routine access to this therapy in SSA. 417 
Furthermore, settings that cannot access this treatment rely on viral sequencing to inform 418 
decision making regarding the most suitable alternative treatment options, but this is also 419 
not routinely available in SSA. It will therefore be crucial for settings such as these to 420 
increase access to newer pangenotypic regimens, as well as testing and documenting 421 
patient genotypes and resistance profiles, in order to monitor the success of first- and 422 
second-line HCV treatments.[67] 423 
 424 
Simplifying the Treatment and Monitoring Phase 425 
Treatment 426 
Despite the availability of curative HCV treatments, most persons infected with HCV 427 
remain untreated.[68] International guidelines recommend that all persons diagnosed with 428 
chronic HCV infection should be considered for treatment.[5-7] Adopting a “treat all” 429 
approach helps to simplify clinical decision-making; streamline patient management; reduce 430 
transmission, morbidity, and mortality; and, ultimately, furthers progress towards WHO 431 
elimination targets. 432 
Access restrictions to HCV treatment remain a significant barrier to care in many 433 
countries.[69,70] Depending upon the country or healthcare system, access can be 434 
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restricted by one or more of the following: high cost, the degree of liver disease (eg, only 435 
patients with progressive liver disease [METAVIR stage ≥F2] can receive DAAs), the 436 
prescribing physician (eg, only specialists can prescribe DAAs), or recent illicit drug or 437 
alcohol abuse (eg, only patients enrolled in an addiction management program or with 438 
demonstrated sobriety can receive DAAs).[69,70] Most restrictions are not evidence-based 439 
or supported by guidelines. For example, guidelines state that recent or active injection drug 440 
use is not a contraindication to HCV therapy.[5-7] Numerous studies have demonstrated a 441 
lack of impact on treatment adherence and high cure rates with DAAs among recent or 442 
active drug users.[71,72] Although these restrictions are slowly being lifted in the United 443 
States, over 30 state Medicaid plans still have prescriber and sobriety restrictions in place, 444 
and ~15 states have fibrosis score restrictions; removing these will improve access to HCV 445 
treatment for all patients and is a key recommendation in the US National Strategy to 446 
eliminate viral hepatitis.[69,70,73] 447 
The latest DAA combinations have transformed the treatment landscape for chronic 448 
HCV infection, offering high cure rates with favorable safety profiles.[7] The fixed-dose DAA 449 
combinations glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are pangenotypic, well-450 
tolerated, have virologic cure rates >95%, and treatment courses of 8–12 weeks for most 451 
patients.[6,7,74,75] 452 
Improving access to HCV treatment worldwide is vital, and in low-to-middle income 453 
countries, generic formulations of approved HCV treatments represent an important step 454 
towards making HCV elimination an achievable goal.[68] Globally, over 60% of people with 455 
HCV infection live in countries with access to affordable generic DAAs,[68] such as generic 456 
formulations of sofosbuvir and daclatasvir, also considered pangenotypic, at costs as low as 457 
approximately US $60 per 12-week supply.[76] Many of these countries have negotiated 458 
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discounts from manufacturers to help provide universal access to HCV treatment with 459 
minimal financial contributions required by patients.[77]  460 
These generic fomulations provide a viable option for HCV treatment, as a recent 461 
systematic review and meta-analysis of the effectiveness of generic formulations 462 
demonstrated equivalent outcomes between generic and licenced DAA formulations in the 463 
treatment of HCV.[78] 464 
The treatment profiles of the pangenotypic DAAs support the practicality of a “treat 465 
all” approach and have already helped to streamline the HCV care pathway by simplifying 466 
treatment choice.[6,7] However there is further room for expansion to include indications 467 
for children under the age of 12 years, who represent an important population to target to 468 
achieve elimination efforts. Indeed, AASLD/IDSA guidelines state that the approval of 469 
additional DAA regimens for children aged 3–11 years is anticipated in the near future,[5] 470 
and sofosbuvir/velpatasvir has recently been approved for use in children from 6 years of 471 
age.[75] 472 
 473 
On-Treatment Monitoring 474 
There appears to be no requirement for on-treatment monitoring for virologic 475 
efficacy, given the very high cure rates with current DAA combinations, and steps towards 476 
simplification with regards to this aspect of HCV treatment have already been made. 477 
AASLD/IDSA guidelines previously recommended that HCV RNA viral load was assessed 4 478 
weeks after treatment initiation, 12 weeks after therapy completion (SVR12), and as a 479 
consideration at the end of treatment.[5] However, evidence suggests HCV RNA 480 
measurements at 4 weeks and at the end of treatment are unnecessary because they are 481 
not predictive of SVR12. In a retrospective review of 208 patients infected with HCV 482 
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receiving DAAs, no difference was reported in SVR12 rates between patients with 483 
detectable and undetectable HCV RNA at week 4 (96.5% vs 97.5%; p=0.69).[79] These 484 
results have been replicated irrespective of treatment regimen or duration.[80,81] 485 
AASLD/IDSA guidelines have recently been updated to dispense with 4-week HCV RNA viral 486 
load assessment, now recommending testing only at 12 or more weeks post-treatment 487 
completion.[5] Furthermore, 2018 EASL recommendations advocate HCV RNA viral load 488 
testing at 12 or 24 weeks post-treatment only but state SVR assessment is dispensable, 489 
given the high cure rates expected with pangenotypic regimens.[6] WHO recommends viral 490 
load testing at 12 or 24 weeks post-treatment.[7] Patients at risk for reinfection should be 491 
tested for SVR12 and yearly thereafter whenever possible.[6] 492 
Another strategy aimed at reducing the reliance on clinic visits and simplifying on-493 
treatment patient monitoring is telemedicine (or telecare). Telemonitoring or teleconsulting 494 
programs, which use telephone contact instead of clinic visits, can be used to ensure 495 
medication adherence and monitor for adverse events and potential drug–drug interactions. 496 
These programs have been successful in underserved populations, such as prisoners.[82] 497 
Simplified HCV treatment monitoring via telephone calls versus standard clinic visits was 498 
assessed in the SMART-C study, and no differences were seen in virologic or safety 499 
outcomes in “easy-to-manage” patients.[83] Taken together with the simplicity, safety, and 500 
effectiveness of the latest DAA regimens, measures aimed at reducing clinic visits, especially 501 
in high prevalence settings, will relieve the burden on healthcare systems.[84] These 502 
strategies will facilitate the retention of patients in care, supporting patients’ preferences 503 
for treatment attributes that offer more convenience and require less disruption to daily life 504 
(eg, shorter treatment duration and fewer office visits).[85] 505 
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In the past, concerns regarding low treatment adherence to interferon-based 
therapies in PWID meant that additional on-treatment monitoring was warranted.[64,86] 
However, in the DAA era, evidence suggests that treatment adherence and SVR rates are 
high in PWID. In the SIMPLIFY study, median adherence to sofosbuvir/velpatasvir for 12 
weeks was 94% in PWID with recent injection drug use (≤6 months), with 32% of patients 
considered non-adherent (<90% adherence).[71] Although adherence decreased during 
therapy, similarly high SVR12 rates were seen in PWID who were adherent (≥90% of doses 
received) and non-adherent (94% vs 94%, p=0.944).[71] In the ongoing ANCHOR study, in 
which 97 PWID with recent injection drug use (≤3 months) received sofosbuvir/velpatasvir 
for 12 weeks, SVR12 was achieved by 90% of PWID who attended the week 24 visit.[72] 
SVR12 rates were unaffected by treatment interruptions that delayed the anticipated 
date for end of treatment, providing the treatment course was completed.[72] Additional 
monitoring for treatment adherence in PWID is no longer warranted; instead, pre-
therapeutic education and on-treatment support delivered via a decentralized 
multidisciplinary care approach are important for successful treatment in PWID. 
 506 
Status: Simplifying the HCV Care Pathway 507 
Simplifying the diagnosis, treatment, and monitoring of patients with chronic HCV 508 
infection has improved the prospects for scaling-up the management of patients by primary 509 
care providers and other non-specialist healthcare professionals to further progress towards 510 
achieving the WHO goal of HCV elimination.[87] AASLD/IDSA acknowledge that treatment 511 
simplification could expand the number of healthcare providers who can prescribe HCV 512 
therapy and increase the number of individuals who are treated.[5] EASL recommendations 513 
are also comprehensive but propose that simplified HCV care pathways are now possible 514 
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using a pangenotypic DAA regimen for 12 weeks.[6] Recent label updates mean that 515 
treatment-naïve patients without cirrhosis or with compensated cirrhosis can now both 516 
receive glecaprevir/pibrentasvir for 8 weeks. The only assessments required are to confirm 517 
chronic HCV infection and advanced fibrosis or cirrhosis (using non-invasive markers) and 518 
establish possible drug–drug interactions. Genotyping can be dispensed with, and SVR12 519 
assessment is not required in, patients who are adherent and not at high risk for 520 
reinfection.[6] WHO also has specific recommendations to support their “treat all and use 521 
pangenotypic DAAs” recommendation, including simplified treatment pathways and 522 
decentralization of testing and treatment services at the primary care level.[7] Simpler HCV 523 
care pathways to encourage HCV testing and treatment at the primary care level have been 524 
successful in expanding treatment in France[88] and Australia,[89] for example. 525 
 526 
Conclusions 527 
Today’s highly effective, safe, and well-tolerated pangenotypic DAA regimens have 528 
maximized the opportunity to simplify treatment strategies in the HCV care pathway. 529 
Recent developments in HCV screening and diagnostic procedures, together with lower 530 
requirements for pre-treatment assessments and on-treatment monitoring, can further 531 
streamline the continuum of care, ensuring more patients are linked to care quickly and 532 
earlier in the disease course, and with minimal clinic visits. These advances also allow HCV 533 
treatment to be prescribed by non-specialist providers, which can reduce overall healthcare 534 
costs and further support efforts towards meeting the WHO viral hepatitis elimination goal. 535 
Patients and healthcare providers should both be motivated to embark on a simplified HCV 536 
care pathway by knowing that, if diagnosed with chronic HCV, the journey from screening to 537 
cure can be achieved in as few as five steps and in as little as 20 to 24 weeks. 538 
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Fig. 1. Overview of the HCV care cascade (A) the traditional care cascade, and (B) a 
potentially simplified HCV care cascade for treatment-naïve patients without cirrhosis 
managed in a primary care setting. 
*Pre-treatment assessments previously recommended by AASLD/IDSA and EASL: HCV genotype and subtype; 
HCV viral load; fibrosis staging; HBV co-infection; HIV co-infection; complete blood count; international 
normalized ratio; hepatic function panel; estimated glomerular filtration rate; potential drug-drug interactions.  
†On-treatment monitoring previously recommended by AASLD/IDSA: HCV viral load; creatinine level; 
estimated glomerular filtration rate; hepatic function panel. 
‡On-treatment monitoring previously recommended by WHO: Routine laboratory monitoring for treatment 
toxicity. 
§Post-SVR12 monitoring recommended by AASLD/IDSA and EASL: surveillance for hepatocellular carcinoma by 
twice-yearly ultrasound examination in patients with advanced fibrosis (ie, Metavir stage F3 or F4). 
¶With reflex testing, screening and diagnosis can be combined to enable confirmatory HCV diagnosis with 
fewer patient visits. AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases 
Society of America; EASL, European Association for the Study of the Liver; HBV, hepatitis B virus; HCV, hepatitis 
C virus; HIV, human immunodeficiency virus; RNA, ribonucleic acid; SVR12, sustained virologic response 12 
weeks after completion of treatment; WHO, World Health Organization  
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Abstract 35 
In 2016, the World Health Organization (WHO) set a target for eliminating viral hepatitis as a 36 
major public health threat by 2030. However, while today’s highly effective and well-37 
tolerated pangenotypic direct-acting antiviral (DAA) regimens have maximized simplification 38 
of HCV treatment, there remain a plethora of barriers to HCV screening, diagnosis and 39 
linkage to care. As of 2017, only 19% of the estimated 71 million individuals living with 40 
chronic hepatitis C virus (HCV) worldwide were diagnosed and in 2015–2016, only 21% of 41 
diagnosed individuals had accessed treatment. Simplification and decentralization of the 42 
HCV care cascade would bolster patient engagement and support the considerable scale-up 43 
needed to achieve WHO targets. Recent developments in HCV screening and diagnosis, 44 
together with reduced pre-treatment assessment and on-treatment monitoring 45 
requirements, can further streamline the care continuum, ensuring patients are linked to 46 
care quickly and earlier in the disease course, and minimize clinic visits. 47 
 48 
Main Concepts and Learning Points 49 
Today’s highly effective, well-tolerated, all-oral, direct-acting antiviral combinations for the treatment 
of chronic hepatitis C virus infection have made elimination of the virus theoretically achievable by 
the World Health Organization’s target of 2030 
Despite the availability of curative hepatitis C virus treatments, most persons infected with hepatitis C 
virus remain untreated 
Recent developments in hepatitis C virus screening and diagnostic procedures, as well as reduced pre-
treatment assessments and on-treatment monitoring requirements, can simplify the hepatitis c virus 
continuum of care 
Simplification of the hepatitis c virus care cascade would facilitate patient engagement and support 
the current concerted effort towards hepatitis c virus elimination 
The journey from hepatitis c virus screening to cure can be achieved in as few as five steps and in as 
little as 20 to 24 weeks 
 50 
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Introduction 52 
The availability of highly effective, well-tolerated, all-oral, direct-acting antiviral 53 
(DAA) combinations for the treatment of chronic hepatitis C virus (HCV) infection has made 54 
the elimination of HCV a theoretically achievable goal within the next decade.[1] In May 55 
2016, the World Health Organization (WHO) adopted their “Global Health Sector Strategy 56 
on Viral Hepatitis, 2016‒2021,” which aims to eliminate viral hepatitis as a major public 57 
health threat by 2030 by reducing new chronic infections by 90% and mortality by 65%. To 58 
achieve this goal, 90% of individuals with chronic HCV infection need to be diagnosed, and 59 
80% of those need to be treated.[2] Worldwide, however, the majority of people infected 60 
with HCV are not diagnosed and, therefore, remain untreated. In 2017, an estimated 71 61 
million individuals were living with chronic HCV worldwide.[3] Of these, it is thought that 62 
only 13.1 million (19%) knew of their infection and only 5 million of those (38%) had 63 
accessed treatment by the end of 2017.[3] Simplification of the HCV care cascade, ideally at 64 
all steps in the continuum of care, would help to ensure that more patients remain engaged 65 
in the care pathway and ultimately support the considerable scale-up needed to achieve 66 
WHO targets.[4] In this article, we review the existing care pathway and discuss potential 67 
opportunities in which the patient journey from HCV screening to cure could be 68 
streamlined. 69 
 70 
Overview of the current HCV care pathway 71 
Depending on the setting, and despite a current concerted effort towards 72 
simplification, the current HCV care pathway can be visualized as a sequence of anywhere 73 
up to 10 steps (Fig. 1A), from screening to cure, as advocated by international guidelines for 74 
HCV management, such as those from the American Association for the Study of Liver 75 
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Diseases (AASLD)/Infectious Diseases Society of America (IDSA),[5] the European Association 76 
for the Study of the Liver (EASL),[6] and WHO.[7] The steps can be grouped into three 77 
distinct phases: screening and diagnosis, pre-treatment, and treatment and monitoring 78 
(including post-treatment follow-up). 79 
 80 
Screening and Diagnosis 81 
The screening and diagnosis phase includes screening for the presence of anti-HCV 82 
antibodies and confirming active HCV replication. Traditionally, screening of individuals at 83 
risk of HCV infection using an anti-HCV antibody test has been widely recommended, with 84 
periodic retesting for those at ongoing risk of (re)infection, such as people who inject drugs 85 
(PWID).[5-7] However, recent guideline updates have seen the broadening of this 86 
recommendation to one-time, routine, opt-out HCV testing for all individuals aged 18 years 87 
and older, with some also recommending testing in the prenatal setting during each 88 
pregnancy.[3,5,8,9] Other screening strategies include birth cohort testing or screening the 89 
general population in areas where HCV seroprevalence is intermediate (≥2%) or high 90 
(≥5%).[6,7] In individuals who are anti-HCV antibody positive, HCV replication is confirmed 91 
using a qualitative/quantitative HCV RNA test.[5-7] HCV core antigen detection and 92 
quantification may also be used to diagnose acute or chronic HCV infection.[6,7] With both 93 
assays, only the presence, not the amount, of marker is used for medical decisions. For 94 
payer reimbursement in some regions, namely the United States and Canada, two separate 95 
HCV RNA tests at least 6 months apart are required to confirm a diagnosis of chronic HCV 96 
infection. Guidelines now recommend that individuals with acute HCV infection are linked to 97 
appropriate care with a healthcare provider who will administer comprehensive 98 
management, rather than waiting for progression to chronic disease.[5,10]  99 
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 100 
Pre-Treatment Phase 101 
For many patients, the pre-treatment phase includes an initial visit to a specialist 102 
(hepatologist, gastroenterologist, or infectious disease specialist) for pre-treatment 103 
assessments and selection of an appropriate HCV treatment. Prior to treatment initiation, a 104 
series of recommended tests are performed to identify viral and host factors that may 105 
impact the choice of treatment, prognosis, and/or required follow-up. In the DAA era, and 106 
with pangenotypic options available, the number of pre-treatment tests has been reduced; 107 
in particular, viral factors (eg, HCV genotype/subtype, presence of HCV drug resistance–108 
associated substitutions) that may have previously impacted viral response and, therefore, 109 
treatment choice are not always required. However, it is still generally important to assess 110 
other active infections, such as hepatitis B virus (HBV) or human immunodeficiency virus 111 
(HIV), and confirm HCV genotype where appropriate.[5-7] Furthermore, it is considered 112 
good clinical practice to assess the degree of liver fibrosis in order to inform treatment 113 
decisions.[5-7] 114 
 115 
Treatment and Monitoring Phase 116 
In most cases, the choice of DAA and treatment duration have been based on HCV 117 
genotype, liver disease severity, and prior HCV treatment status. AASLD/IDSA guidance and 118 
2018 EASL recommendations advocate ribavirin-free DAA regimens, preferably 119 
pangenotypic if available (ie, those effective against the main HCV genotypes 1‒6), for HCV 120 
treatment-naïve or -experienced adults without cirrhosis or with compensated cirrhosis.[3] 121 
Ribavirin is required in patients with decompensated cirrhosis.[5,6] In addition, EASL 122 
guidelines recommend combination regimens comprising two rather than three DAAs to 123 
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minimize the risk of adverse effects or drug–drug interactions.[6] Finally, WHO guidelines 124 
only recommend pangenotypic DAA regimens for all adults with or without cirrhosis.[7] 125 
Although DAAs are generally well-tolerated, patients should be assessed for adverse 126 
events or potential drug–drug interactions at each visit or, according to WHO guidelines, at 127 
the end of treatment.[5-7] HBV reactivation during or after DAA treatment has been 128 
reported in patients who are hepatitis B surface antigen–positive and not receiving HBV 129 
antiviral therapy.[5] Therefore, patients meeting criteria for active HBV infection should be 130 
started on HBV antiviral therapy. Patients with low or undetectable HBV DNA levels can 131 
either receive prophylactic HBV therapy or be monitored for HBV reactivation during and 132 
immediately after HCV DAA therapy; HBV therapy should be initiated in patients with 133 
evidence of HBV reactivation.[5-7] 134 
The final monitoring step is assessment of HCV cure, defined as a sustained virologic 135 
response (SVR; ie, undetectable HCV RNA) 12 weeks after completion of treatment 136 
(SVR12).[5-7] Some guidelines suggest SVR at 24 weeks after completion of treatment 137 
(SVR24) can also be used to define cure[6,7]; however, because of the high rate of 138 
concordance between SVR12 and SVR24 (sensitivity and specificity of 99% and 98%, 139 
respectively), the US Food and Drug Administration, and AASLD/IDSA guidelines, have 140 
defined HCV cure as SVR12.[5,11] Some patients may require additional monitoring, for 141 
instance to minimize drug–drug interactions between HCV DAAs and anti-HIV medications 142 
or immunosuppressants that could jeopardize graft success in liver transplant 143 
recipients.[5,6] Patients with advanced cirrhosis should also be monitored closely during 144 
treatment, and for hepatocellular carcinoma (HCC) after treatment.[5-7] 145 
 146 
Simplifying the HCV Care Pathway 147 
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The current HCV care pathway is complex and often difficult to navigate for many 148 
patients, with multiple office visits, blood draws, assessments, and interactions with 149 
different healthcare providers and payers. This level of continuous care can be a particularly 150 
challenging barrier in some populations that require specific public health approaches 151 
because of a high incidence of HCV, high prevalence of HCV, stigma, discrimination, 152 
criminalization or vulnerability, and/or difficulty accessing healthcare services, such that 153 
they would benefit from a streamlined care pathway.[7] Examples of such populations 154 
include PWID, prisoners, homeless individuals, migrants, those in rural communities with 155 
poor access to care, those struggling with mental health or substance use disorders, some 156 
groups of men who have sex with men, sex workers, and indigenous populations who are 157 
historically less engaged in healthcare. In addition, the current pathway requires high-level 158 
laboratory and clinical capabilities to diagnose infection, identify the HCV genotype, assess 159 
fibrosis, and monitor treatment. These requirements potentially create barriers for HCV care 160 
management. 161 
Based on recent advances in diagnostic techniques and HCV treatments, the current 162 
HCV care pathway can be streamlined (Fig. 1B), and simplification of care is an increasing 163 
focus within the field of HCV treatment.[4] Simplification will potentially have multiple 164 
benefits, including better allocation of resources to diagnose and treat more patients 165 
(expanding access and coverage), acceleration of treatment initiation (linkage to care), 166 
reduction in HCV transmission among high-risk populations (treatment as prevention), 167 
improvement in patient adherence, facilitation of task-sharing/patient management by non-168 
specialists, and lowering the long-term medical costs of untreated HCV infection, such as 169 
those associated with advanced liver disease, extra-hepatic complications of HCV infection, 170 
or liver transplant. 171 
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For many patients, the ideal HCV care pathway would involve diagnosis, pre-172 
treatment work up, and treatment initiation in a single day. A US study modeled the impact 173 
of a hypothetical “consolidated” HCV care pathway that required at least two visits for 174 
patients to receive treatment.[12] In this scenario, a positive anti-HCV test led immediately 175 
to an HCV RNA test, HCV genotyping, and fibrosis staging, which took place during a single 176 
visit. Referral to a specialist was required only for patients with moderate to advanced 177 
fibrosis (METAVIR stage ≥F2); therefore, an estimated 40% of patients could be managed by 178 
their primary care provider. Compared with the current HCV care pathway that requires at 179 
least four visits before receiving treatment, the consolidated pathway reduced the 180 
percentage of patients lost to follow-up from screening to treatment from 71‒76% 181 
(depending upon the insurance provider) to 4‒5%. Therefore, reducing the steps in the care 182 
pathway increased the number of patients who learned of their HCV status, were linked to 183 
care, and received HCV treatment. The cost to identify and link to care one additional 184 
patient with HCV was $1586‒$2546 with the current HCV care pathway and $212‒$548 with 185 
the consolidated pathway.[12] However, these findings may not be generalizable to all 186 
geographical settings or certain high-risk populations. 187 
 188 
Simplifying the Screening and Diagnosis Phase 189 
Screening and diagnostic services need to reach much larger numbers of individuals 190 
with HCV infection to achieve the WHO elimination target of 90% diagnosed by 2030. 191 
Strategies to increase anti-HCV screening and diagnosis rates include risk factor–based 192 
screening, universal screening in specific populations, simplification of sampling using 193 
capillary whole blood, dried blood spot (DBS) testing, and point-of-care (PoC) testing using 194 
rapid diagnostic tests (RDTs). 195 
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 196 
Screening Programs 197 
Risk factor–based anti-HCV screening has previously been a prominent feature of 198 
international guidelines. However, screening for specific risk factors for HCV infection (ie, 199 
risk behaviors or exposures) has largely been unsuccessful because of patients’ reluctance 200 
to disclose these risks and provider limitations in collecting risk information.[5] Population-201 
based screening methods may be more successful (ie, identifying and screening populations 202 
that have a relatively high prevalence of HCV infection). For example, in the United States, 203 
50% of all HCV infections occur in individuals born between 1945 and 1965; therefore, one-204 
time HCV testing has been recommended in this birth cohort.[13] Nevertheless, screening 205 
rates are still low in this population because of, among other reasons, the stigma associated 206 
with HCV infection, the asymptomatic course of the disease, the lack of awareness of testing 207 
recommendations, and low healthcare engagement of the most at-risk populations.[14]  208 
However, recent guideline updates have seen recommendations for screening 209 
broaden to include routine one-time HCV testing for all individuals aged 18 years and 210 
older.[3,5,8,9] Practical implementation measures, such as electronic medical record 211 
prompts, that have been shown to significantly increase screening rates in individuals born 212 
between 1945 and 1965 may help to facilitate universal screening and alleviate any stigma 213 
related to the disease. For example, in one study of this demographic group, screening rates 214 
increased from 7.6% during the 6 months before their introduction to 72% over the year 215 
after their introduction.[15] 216 
PWID have been identified as a priority population for HCV elimination. Worldwide, 217 
approximately 40% of people with recent injecting drug use are infected with HCV and 9% of 218 
all people living with HCV infection are those who recently injected drugs, with wide 219 
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variation among countries.[16] It has been estimated that 43% of all new HCV infections 220 
could be prevented over 12 years (2018–2030) if the HCV transmission risk associated with 221 
PWID was removed over that period.[17] Uptake of HCV treatment in this group is 222 
historically low,[18] despite guideline recommendations to regularly screen PWID for 223 
HCV.[5-7] The challenge for screening this population is the lack of engagement with 224 
traditional sources of healthcare; therefore, alternative options must be explored. One 225 
successful strategy is to integrate HCV screening programs into harm reduction and 226 
community outreach facilities, thereby offering a comprehensive “one-stop strategy” at the 227 
PoC for HCV screening and diagnosis, treatment initiation, and follow-up. Such approaches 228 
have been successfully implemented in several countries including France,[19] 229 
Switzerland,[20] and the United States.[21] In Scotland, the launch of the Hepatitis C Action 230 
Plan introduced DBS sampling into community drug services to increase access to 231 
testing.[22] Between the pre–Action Plan (1999–2006) and Action Plan (2007–2011) 232 
periods, the average number of annual tests increased from 67 to 973; the percentage of 233 
individuals testing positive for HCV also increased across these periods (from 19% to 38%). 234 
Unfortunately, screening birth cohorts and high-risk populations such as PWID will 235 
not find all of the remaining individuals infected with HCV. Achieving WHO elimination 236 
targets will require the adoption of broader, simpler screening policies. Different regional 237 
strategies will be needed because of the variable global epidemiology of HCV infection.[16] 238 
One strategy under consideration is universal anti-HCV screening of all adults. Egypt, which 239 
has the highest prevalence of HCV worldwide and access to low-cost generic DAA 240 
treatments, has embarked on one such program: following a campaign of targeted 241 
screening, all adults aged 18 years and older are now being screened.[23] This approach 242 
may be too costly in regions with low HCV prevalence because of the large number of 243 
  12 
patients needed to be screened. However, modeling studies in France and the United States 244 
have shown universal screening can be cost-effective in low prevalence regions.[24,25] 245 
Indeed, the US Preventative Services Task Force has recently updated their 246 
recommendations to include HCV screening for all adults 18–79 years of age.[8] Likewise, 247 
the US Centers for Disease Control & Prevention (CDC) recently proposed draftupdated their 248 
recommendations to include screening of all adults aged 18 years and older in addition to all 249 
pregnant women; except in settings where the prevalence of HCV is less than 0.1%.[9]  250 
HCV screening in pregnancy represents an important opportunity for healthcare 251 
provider interaction with women of childbearing age, in whom rates of HCV have been 252 
increasing in recent years.[26] The prevalence of HCV antibodies in pregnant women is 253 
thought to be 0.1–3.6% worldwide, and some studies suggest that chronic HCV infection is 254 
associated with an increased risk for adverse neonatal outcomes.[27] Furthermore, vertical 255 
transmission of HCV from mother to child will occur in up to 5% of cases of HCV 256 
monoinfection and is a common source of HCV infection in children.[28]   257 
Around 3.5 million children are estimated to be infected globally,[28] representing 258 
an important pool of unidentified HCV cases, with as many as 95% of HCV-infected children 259 
in the United States of America remaining undiagnosed.[29] In one study including 119 260 
perinatally infected patients, 38% of those aged >33 years had developed cirrhosis, despite 261 
the low prevalence of traditional risk factors.[30] 262 
Alternatively, pragmatic approaches to screening strategies, such as random 263 
selection or using a hub-and-spoke model as trialed in Italy, can provide a practical 264 
compromise between universal and targeted screening.[31] 265 
Regardless of the model employed and populations targeted, screening to identify 266 
undiagnosed cases is vital in achieving elimination targets. 267 
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 268 
Virologic Tools to Simplify HCV Screening 269 
PoC testing provided outside traditional centralized laboratories can be used with 270 
the goal of delivering test results to patients during the same visit.[32] PoC testing relies 271 
extensively on the use of one of the many RDTs available for anti-HCV antibody detection, 272 
several of which are prequalified by WHO.[33] RDTs can be performed in 20 minutes for 273 
anti-HCV antibodies using whole blood obtained by venipuncture or finger prick, or oral 274 
fluid. Anti-HCV antibody RDTs have excellent sensitivity and specificity compared with ELISA-275 
based laboratory methods (98% and 100%, respectively).[34] RDTs are valuable in high-276 
throughput settings where results are needed quickly, such as prisons and harm reduction 277 
programs. An example of the value of RDTs within a harm reduction setting is provided by 278 
Bregenzer et al., where the introduction of an anti-HCV antibody RDT led to 23.9% of PWID 279 
undergoing HCV screening, compared with only 2% prior to its introduction.[35] 280 
Confirmation of infection after detection of anti-HCV antibodies requires HCV RNA or core 281 
antigen testing. A few PoC HCV RNA assays, which generate results from plasma or whole 282 
blood within 60 to 90 minutes, are available.[32] The increasing availability of such assays in 283 
high-income settings has the potential to transform HCV testing. In low-income countries, 284 
providers need to take advantage of the availability of such technologies, which to date 285 
have typically been used for HIV or tuberculosis testing. 286 
To meet the WHO goal of identifying 90% of all HCV-infected individuals, PoC testing 287 
needs to be implemented into non-traditional settings to capture individuals not actively 288 
engaged in healthcare, including emergency departments, obstetric centers, surgical and 289 
psychiatric wards, dental clinics, and pharmacies.[36-41] Potential benefits of increased PoC 290 
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testing include reducing the number of clinic visits, which may increase screening and 291 
treatment rates, and reducing late presentation, which is common in patients with HCV.[42]  292 
Using DBS samples is an alternative method to PoC testing. A few drops of fingerstick 293 
whole blood are placed onto a special absorbent filter paper. After desiccation, DBS can be 294 
shipped as non-hazardous materials using regular mail or courier services to reference 295 
laboratories for anti-HCV antibody and HCV RNA assessments.[32] DBS diagnostic accuracy 296 
is high for anti-HCV antibodies (sensitivity, 96.1%; specificity, 99.2%) and HCV RNA 297 
(sensitivity, 97.8%; specificity, 99.2%), with no relevant differences in diagnostic accuracy 298 
according to the type of test used.[43] DBS has distinct advantages over blood and oral fluid 299 
in terms of ease of transport and storage and may be particularly useful in low- and middle-300 
income countries with high HCV prevalence and limited healthcare infrastructure. In high-301 
income countries, DBS could be used where facilities and treatment for PWID or migrant 302 
populations are community located and staffed by workers with limited clinical training.  303 
 304 
Methods to Improve Linkage to Care 305 
In addition to increasing screening rates, loss to follow-up between screening and 306 
diagnosis must be reduced. Studies in Europe and the United States show that 69% and 47% 307 
of screened patients, respectively, did not receive a confirmatory diagnosis of HCV 308 
infection.[44,45] Some countries have higher diagnosis rates, particularly those with 309 
national screening plans, such as France (74%) and Australia (75%).[46,47] Reinforcing the 310 
link between screening and diagnosis will ensure better identification of infected individuals 311 
and improve rates of retention in the HCV care pathway. The screening and diagnosis phase 312 
will continue to be a two-step process until it becomes more cost-effective to perform a 313 
single HCV RNA test to confirm active HCV infection (eg, in areas with very high HCV 314 
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prevalence). Alternatively, advances such as reflex testing combine these steps into a single 315 
clinic visit.  316 
Reflex HCV RNA testing, in which a positive anti-HCV test triggers an immediate HCV 317 
RNA test on the same sample, eliminates an extra visit for a new sample and enables more 318 
rapid linkage to care.[12] Reflex HCV RNA testing, as used by the US Veterans Affairs (VA) 319 
system,[48] is important in large health systems, with centralized testing where most 320 
patients are actively engaged in care and undergoing phlebotomy rather than PoC 321 
testing.[48] However, this approach may be suitable for some field-based PoC approaches 322 
outlined above. AASLD/IDSA guidelines recommend that harm reduction programs offer 323 
anti-HCV testing with reflex or immediate confirmatory HCV RNA testing,[5] 2018 EASL 324 
recommendations state that reflex HCV RNA testing should be applied whenever 325 
possible,[6] and WHO guidelines include reflex HCV RNA testing as an approach to promote 326 
linkage to care in all patients with HCV.[7] 327 
Increases in screening and diagnosis rates will have a limited impact on WHO 328 
elimination targets without concomitant improvements in linkage to care. Although 329 
specialist referral may be required for some complex cases, most patients could be treated 330 
by their primary care provider if the providers were given adequate training.[7] Therefore, 331 
the role of the primary care provider is considered critical for expanding access to HCV care, 332 
especially in areas of high HCV prevalence.[49] Recently released “Simplified HCV Treatment 333 
Algorithms” from AASLD/IDSA reinforce the concept that less complex cases can be 334 
successfully managed by primary care providers with less intensive monitoring.[50,51] 335 
Indeed, providing  decentralizing HCV treatment to utilize primary care physicians 336 
significantly increased treatment uptake in PWID in Australia and New Zealand compared 337 
with hospital-based specialist care (75% vs 34%), with significantly higher cure rates (49% vs 338 
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30%).[52] Telementoring programs can be used to educate and support non-specialist 339 
providers. These programs take advantage of approaches such as videoconferencing and 340 
knowledge networks to establish close collaborations between HCV specialists and primary 341 
care providers or other healthcare professionals. One such program, the VA-Extension for 342 
Community Healthcare Outcomes (ECHO) program, demonstrated an increase in the rate of 343 
primary care provider–initiated HCV treatment from 2.5% to 21.4% (p<0.01) with program 344 
participation.[53] The ECHO model also demonstrated that HCV treatment administered by 345 
non-specialist providers was as safe and effective as that provided by specialists in 346 
underserved populations.[54] An alternative telementoring approach investigated in the 347 
ASCEND study indicates that under specialist oversight, nurse practitioners or primary care 348 
physicians only required a short 3-hour training session to treat patients as effectively as 349 
specialists.[55] Shifting Decentralizing HCV care from specialists to primary care providers, 350 
as well as other healthcare professionals such as addiction specialists, prison doctors, and 351 
advanced practice providers, would simplify the continuum of care and expand access to 352 
HCV treatments without compromising outcomes.[56] Furthermore, integrating HCV care 353 
pathways with those for common copathologies such as HIV, malaria or sexually transmitted 354 
diseases represents another important method for expanding access to HCV diagnosis and 355 
treatment[57-59] and can increase HCV diagnosis and treatment uptake.[59,60] 356 
 357 
Simplifying the Pre-Treatment Phase 358 
Assessing Liver Fibrosis 359 
Once chronic HCV infection has been confirmed, patients undergo several pre-360 
treatment assessments.[5-7] Staging of liver fibrosis by at least one method is required for 361 
all patients prior to treatment to determine the need for post-treatment monitoring (ie, bi-362 
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annual HCC ultrasound screening) in patients with advanced fibrosis (METAVIR score F3) or 363 
cirrhosis (METAVIR score F4).[5-7] If advanced fibrosis or cirrhosis is present, these patients 364 
should be referred to a specialist provider for their continued care requirements. However, 365 
the remaining population with HCV infection is evolving to generally be younger and have 366 
milder liver disease,[61,62] which may help to support more non-specialist provider 367 
involvement.  368 
Although biopsy was previously used for assessing liver fibrosis, the procedure is 369 
invasive and minor complications are common. Alternative, validated and non-invasive 370 
methods including serologic, physical, and imaging protocols have replaced biopsy and are 371 
preferred to stage liver fibrosis.[63] Simplifying the initial liver fibrosis assessment using 372 
non-invasive methods would enable decision-making by non-specialist providers, which 373 
would reduce referrals to specialists and improve access to care for patients. This could be 374 
particularly impactful for high-risk groups, such as PWID, who may already be managed in a 375 
number of health care settings.[64,65]  376 
The calculation of an aspartate aminotransferase (AST)-to-platelet ratio index (APRI) 377 
score using AST concentrations and platelet count has excellent negative predictive value 378 
and can identify patients not at risk for advanced liver fibrosis who could be easily managed 379 
by non-specialist providers.[63] In a prospective study in treatment-naïve patients 380 
chronically infected with HCV genotype 1‒6 and no history of cirrhosis, APRI ≤1 was used to 381 
select patients for 8 weeks’ treatment with the pangenotypic DAA combination 382 
glecaprevir/pibrentasvir.[66] The results showed that APRI ≤1 (mean, 0.41; range, 0.13‒383 
1.00) identified patients without cirrhosis who could then be appropriately treated by non-384 
specialist providers. Fibrosis-4 (FIB-4) is another tool that uses a formula based on age, AST, 385 
platelets, and alanine aminotransferase to score fibrosis.[63] FibroTest is a laboratory-386 
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ordered test using a proprietary formula based on age, gender, and five additional 387 
biomarkers.[63] Transient elastography (eg, FibroScan®) measures liver stiffness to assess 388 
fibrosis; in addition, other physical technologies have been developed to assess liver 389 
fibrosis.[63] FibroScan and FibroTest use may be restricted by cost and availability in 390 
resource-limited settings. AASLD/IDSA guidelines recommend liver biopsy and/or non-391 
invasive markers to evaluate liver fibrosis in patients with chronic HCV infection.[5] The new 392 
simplified algorithms from AASLD/IDSA emphasize the utility of non-invasive tests for 393 
fibrosis assessment.[50,51] EASL and WHO guidelines recommend non-invasive methods, 394 
especially APRI and FIB-4, outside specialty clinics in resource-limited settings.[6,7] 395 
 396 
HCV Genotype Determination 397 
With the introduction of pangenotypic DAAs, some guidelines consider that the need 398 
for HCV genotyping is reduced, particularly where tests are not available or not affordable, 399 
or to improve access by simplifying the care pathway.[5-7] However, identifying patients 400 
infected with genotype 3, particularly those who have cirrhosis, remains important because 401 
SVR rates can be impacted by prior HCV treatment experience or the presence of NS5A 402 
inhibitor resistance–associated substitutions at baseline.[5-7] Longer treatment durations, 403 
baseline resistance testing, or the addition of a third drug (eg, a DAA with another target or 404 
ribavirin) may be required in patients with HCV genotype 3 infection and cirrhosis. The 405 
decision to identify the HCV genotype may ultimately be one of cost-effectiveness (ie, 406 
relative cost of regimens without genotype 3 restrictions) and the epidemiologic profile of 407 
endemic HCV genotypes within specific regions. WHO guidelines stipulate that where HCV 408 
genotype 3 prevalence is <5%, genotyping could be excluded and a uniform pangenotypic 409 
treatment duration used.[7] 410 
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However, the prevalence of other potentially difficult-to-treat genotypes such as non-1a/b 411 
subtypes of GT1 or non-4a/d subtypes of GT4 are increasing worldwide, largely driven by 412 
migration from areas of high endemicity for these subtypes, such as sub-Saharan Africa 413 
(SSA).[67] These subtypes are associated with higher failure rates to earlier NS5A inhibitors 414 
than other subtypes, with sofosbuvir/velpatasvir/voxilaprevir the only currently approved 415 
re-treatment option for those failing initial NS5A-based regimens.[67] This potentially poses 416 
a barrier to re-treatment success, as there is limited routine access to this therapy in SSA. 417 
Furthermore, settings that cannot access this treatment rely on viral sequencing to inform 418 
decision making regarding the most suitable alternative treatment options, but this is also 419 
not routinely available in SSA. It will therefore be crucial for settings such as these to 420 
increase access to newer pangenotypic regimens, as well as testing and documenting 421 
patient genotypes and resistance profiles, in order to monitor the success of first- and 422 
second-line HCV treatments.[67] 423 
 424 
Simplifying the Treatment and Monitoring Phase 425 
Treatment 426 
Despite the availability of curative HCV treatments, most persons infected with HCV 427 
remain untreated.[68] International guidelines recommend that all persons diagnosed with 428 
chronic HCV infection should be considered for treatment.[5-7] Adopting a “treat all” 429 
approach helps to simplify clinical decision-making; streamline patient management; reduce 430 
transmission, morbidity, and mortality; and, ultimately, furthers progress towards WHO 431 
elimination targets. 432 
Access restrictions to HCV treatment remain a significant barrier to care in many 433 
countries.[69,70] Depending upon the country or healthcare system, access can be 434 
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restricted by one or more of the following: high cost, the degree of liver disease (eg, only 435 
patients with progressive liver disease [METAVIR stage ≥F2] can receive DAAs), the 436 
prescribing physician (eg, only specialists can prescribe DAAs), or recent illicit drug or 437 
alcohol abuse (eg, only patients enrolled in an addiction management program or with 438 
demonstrated sobriety can receive DAAs).[69,70] Most restrictions are not evidence-based 439 
or supported by guidelines. For example, guidelines state that recent or active injection drug 440 
use is not a contraindication to HCV therapy.[5-7] Numerous studies have demonstrated a 441 
lack of impact on treatment adherence and high cure rates with DAAs among recent or 442 
active drug users.[71,72] Although these restrictions are slowly being lifted in the United 443 
States, over 30 state Medicaid plans still have prescriber and sobriety restrictions in place, 444 
and ~15 states have fibrosis score restrictions; removing these will improve access to HCV 445 
treatment for all patients and is a key recommendation in the US National Strategy to 446 
eliminate viral hepatitis.[69,70,73] 447 
The latest DAA combinations have transformed the treatment landscape for chronic 448 
HCV infection, offering high cure rates with favorable safety profiles.[7] The fixed-dose DAA 449 
combinations glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are pangenotypic, well-450 
tolerated, have virologic cure rates >95%, and treatment courses of 8–12 weeks for most 451 
patients.[6,7,74,75] 452 
 In addition,Improving access to HCV treatment worldwide is vital, and in low-to-453 
middle income countries, generic formulations of approved HCV treatments represent an 454 
important step towards making HCV elimination an achievable goal.[68] Globally, over 60% 455 
of people with HCV infection live in countries with access to affordable generic DAAs,[68] 456 
such as generic formulations of sofosbuvir and daclatasvir, also considered pangenotypic, 457 
are now widely available in low- and middle-income countries at costs as low as 458 
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approximately US $60 per 12-week supply.[76] Many of these countries have negotiated 459 
discounts from manufacturers to help provide universal access to HCV treatment with 460 
minimal financial contributions required by patients.[77]  461 
These generic fomulations provide a viable option for HCV treatment, as a recent 462 
systematic review and meta-analysis of the effectiveness of generic formulations 463 
demonstrated equivalent outcomes between generic and licenced DAA formulations in the 464 
treatment of HCV.[78] 465 
 These treatment profiles of the pangenotypic DAAs support the practicality of a 466 
“treat all” approach and have already helped to streamline the HCV care pathway by 467 
simplifying treatment choice.[6,7] However there is further room for expansion to include 468 
indications for children under the age of 12 years, who represent an important population 469 
to target to achieve elimination efforts. Indeed, AASLD/IDSA guidelines state that the 470 
approval of additional DAA regimens for children aged 3–11 years is anticipated in the near 471 
future,[5] and sofosbuvir/velpatasvir has recently been approved for use in children from 6 472 
years of age.[75] 473 
 474 
On-Treatment Monitoring 475 
There appears to be no requirement for on-treatment monitoring for virologic 476 
efficacy, given the very high cure rates with current DAA combinations, and steps towards 477 
simplification with regards to this aspect of HCV treatment have already been made. 478 
AASLD/IDSA guidelines previously recommended that HCV RNA viral load was assessed 4 479 
weeks after treatment initiation, 12 weeks after therapy completion (SVR12), and as a 480 
consideration at the end of treatment.[5] However, evidence suggests HCV RNA 481 
measurements at 4 weeks and at the end of treatment are unnecessary because they are 482 
  22 
not predictive of SVR12. In a retrospective review of 208 patients infected with HCV 483 
receiving DAAs, no difference was reported in SVR12 rates between patients with 484 
detectable and undetectable HCV RNA at week 4 (96.5% vs 97.5%; p=0.69).[79] These 485 
results have been replicated irrespective of treatment regimen or duration.[80,81] 486 
AASLD/IDSA guidelines have recently been updated to dispense with 4-week HCV RNA viral 487 
load assessment, now recommending testing only at 12 or more weeks post-treatment 488 
completion.[5] Furthermore, 2018 EASL recommendations advocate HCV RNA viral load 489 
testing at 12 or 24 weeks post-treatment only but state SVR assessment is dispensable, 490 
given the high cure rates expected with pangenotypic regimens.[6] WHO recommends viral 491 
load testing at 12 or 24 weeks post-treatment.[7] Patients at risk for reinfection should be 492 
tested for SVR12 and yearly thereafter whenever possible.[6] 493 
Another strategy aimed at reducing the reliance on clinic visits and simplifying on-494 
treatment patient monitoring is telemedicine (or telecare). Telemonitoring or teleconsulting 495 
programs, which use telephone contact instead of clinic visits, can be used to ensure 496 
medication adherence and monitor for adverse events and potential drug–drug interactions. 497 
These programs have been successful in underserved populations, such as prisoners.[82] 498 
Simplified HCV treatment monitoring via telephone calls versus standard clinic visits was 499 
assessed in the SMART-C study, and no differences were seen in virologic or safety 500 
outcomes in “easy-to-manage” patients.[83] Taken together with the simplicity, safety, and 501 
effectiveness of the latest DAA regimens, measures aimed at reducing clinic visits, especially 502 
in high prevalence settings, will relieve the burden on healthcare systems.[84] These 503 
strategies will facilitate the retention of patients in care, supporting patients’ preferences 504 
for treatment attributes that offer more convenience and require less disruption to daily life 505 
(eg, shorter treatment duration and fewer office visits).[85] 506 
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In the past, concerns regarding low treatment adherence to interferon-based 
therapies in PWID meant that additional on-treatment monitoring was warranted.[64,86] 
However, in the DAA era, evidence suggests that treatment adherence and SVR rates are 
high in PWID. In the SIMPLIFY study, median adherence to sofosbuvir/velpatasvir for 12 
weeks was 94% in PWID with recent injection drug use (≤6 months), with 32% of patients 
considered non-adherent (<90% adherence).[71] Although adherence decreased during 
therapy, similarly high SVR12 rates were seen in PWID who were adherent (≥90% of doses 
received) and non-adherent (94% vs 94%, p=0.944).[71] In the ongoing ANCHOR study, in 
which 97 PWID with recent injection drug use (≤3 months) received sofosbuvir/velpatasvir 
for 12 weeks, SVR12 was achieved by 90% of PWID who attended the week 24 visit.[72] 
SVR12 rates were unaffected by treatment interruptions that delayed the anticipated 
date for end of treatment, providing the treatment course was completed.[72] Additional 
monitoring for treatment adherence in PWID is no longer warranted; instead, pre-
therapeutic education and on-treatment support delivered via a decentralized 
multidisciplinary care approach are important for successful treatment in PWID. 
 507 
Status: Simplifying the HCV Care Pathway 508 
Simplifying the diagnosis, treatment, and monitoring of patients with chronic HCV 509 
infection has improved the prospects for scaling-up the management of patients by primary 510 
care providers and other non-specialist healthcare professionals to further progress towards 511 
achieving the WHO goal of HCV elimination.[87] AASLD/IDSA acknowledge that treatment 512 
simplification could expand the number of healthcare providers who can prescribe HCV 513 
therapy and increase the number of individuals who are treated.[5] EASL recommendations 514 
are also comprehensive but propose that simplified HCV care pathways are now possible 515 
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using a pangenotypic DAA regimen for 12 weeks.[6] Recent label updates mean that 516 
treatment-naïve patients without cirrhosis or with compensated cirrhosis can now both 517 
receive glecaprevir/pibrentasvir for 8 weeks. The only assessments required are to confirm 518 
chronic HCV infection and advanced fibrosis or cirrhosis (using non-invasive markers) and 519 
establish possible drug–drug interactions. Genotyping can be dispensed with, and SVR12 520 
assessment is not required in, patients who are adherent and not at high risk for 521 
reinfection.[6] WHO also has specific recommendations to support their “treat all and use 522 
pangenotypic DAAs” recommendation, including simplified treatment pathways and 523 
decentralization of testing and treatment services at the primary care level.[7] Simpler HCV 524 
care pathways to encourage HCV testing and treatment at the primary care level have been 525 
successful in expanding treatment in France[88] and Australia,[89] for example. 526 
 527 
Conclusions 528 
Today’s highly effective, safe, and well-tolerated pangenotypic DAA regimens have 529 
maximized the opportunity to simplify treatment strategies in the HCV care pathway. 530 
Recent developments in HCV screening and diagnostic procedures, together with lower 531 
requirements for pre-treatment assessments and on-treatment monitoring, can further 532 
streamline the continuum of care, ensuring more patients are linked to care quickly and 533 
earlier in the disease course, and with minimal clinic visits. These advances also allow HCV 534 
treatment to be prescribed by non-specialist providers, which can reduce overall healthcare 535 
costs and further support efforts towards meeting the WHO viral hepatitis elimination goal. 536 
Patients and healthcare providers should both be motivated to embark on a simplified HCV 537 
care pathway by knowing that, if diagnosed with chronic HCV, the journey from screening to 538 
cure can be achieved in as few as five steps and in as little as 20 to 24 weeks. 539 
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Fig. 1. Overview of the HCV care cascade (A) the traditional care cascade, and (B) a 
potentially simplified HCV care cascade for treatment-naïve patients without cirrhosis 
managed in a primary care setting. 
*Pre-treatment assessments previously recommended by AASLD/IDSA and EASL: HCV genotype and subtype; 
HCV viral load; fibrosis staging; HBV co-infection; HIV co-infection; complete blood count; international 
normalized ratio; hepatic function panel; estimated glomerular filtration rate; potential drug-drug interactions.  
†On-treatment monitoring previously recommended by AASLD/IDSA: HCV viral load; creatinine level; 
estimated glomerular filtration rate; hepatic function panel. 
‡On-treatment monitoring previously recommended by WHO: Routine laboratory monitoring for treatment 
toxicity. 
§Post-SVR12 monitoring recommended by AASLD/IDSA and EASL: surveillance for hepatocellular carcinoma by 
twice-yearly ultrasound examination in patients with advanced fibrosis (ie, Metavir stage F3 or F4). 
*¶With reflex testing, screening and diagnosis can be combined to enable confirmatory HCV diagnosis with 
fewer patient visits. AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases 
Society of America; EASL, European Association for the Study of the Liver; HBV, hepatitis B virus; HCV, hepatitis 
C virus; HIV, human immunodeficiency virus; RNA, ribonucleic acid; SVR12, sustained virologic response 12 
weeks after completion of treatment; WHO, World Health Organization  
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